Hundreds turn out for Walk MS event at Outer Harbor
Walk MS, which has raised over $1 billion for the National Multiple Sclerosis Society's mission to cure the disease, kicked off in a new location this year at the Outer Harbor.
Mike Calandra, who was diagnosed with MS six years ago when he was 24, was honored this year.
'I definitely feel blessed,' Calandra said. 'There's a lot of people that are here that have MS that would make great honorees as well. I don't take it lightly that they chose me and I feel very fortunate.'
It was Kimberly Zackey's 10th year participating after she was diagnosed in 2012.
'Since there's so many things with MS that are out of my control, I thought fundraising efforts and bringing people together for this cause is something that we can do,' Zackey said. 'Just like with MS, ups and downs — some days it's sunny, some days it's rainy. But we're all here and I appreciate everyone coming out and being together.'
Organizers said Walk MS is the biggest fundraiser of the year for the National Multiple Sclerosis Society, which has funded the research behind every major breakthrough in treating the disease of the central nervous system.
'I always use this as an opportunity to put out there all about MS, what it is, what we can do about it and not to hide behind the diagnosis, but celebrate it and know that we're all going to be OK if we work together,' Zackey said.
Western New York has a very high rate of MS. The event provides community and hope for those affected by the disease.
'Any disease, but maybe MS especially, can be a little isolating, so to come here and have this community camaraderie with people that love and want to help you makes all the difference,' said Andy Yates, president of the Upstate Chapter of the National MS Society.
'It's empowering. It shows me in my own life that I'm capable of anything,' said Sarah Nicoletti, who was walking in support of her friend. 'If these people can overcome this, they're like leaders to me.'
WIVB News 4 has been a longtime supporter of Walk MS and after 37 years of being emcee, Jacquie Walker told the crowd this is her final year in that role. She introduced Marlee Tuskes as the emcee of Walk MS 2026.
Sarah Minkewicz is an Emmy-nominated reporter and Buffalo native who has been a part of the News 4 team since 2019. Follow Sarah on Twitter @SarahMinkewicz and click here to see more of her work.
***
Jacquie Walker is an award-winning anchor and reporter who has been part of the News 4 team since 1983. See more of her work here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 hours ago
- Yahoo
Skittles, M&M's more candy options free of synthetic dyes coming in 2026
Starting next year, Skittles, M&M's, Starburst and Extra Gum will be available free of artificial colors to consumers nationwide. Mars Wrigley North America announced last month that products across four categories of its popular treats -- gum, fruity confections and chocolate candy -- will be made "without Food, Drug & Cosmetic (FD&C) colors" starting in 2026. The first brands to be available without without FD&C colors will include M&M's Chocolate, Skittles Original, Extra Gum Spearmint and Starburst Original fruit chews, the company said. Kraft Heinz, General Mills to remove artificial dyes from food products over next 2 years News of the candy maker's move away from synthetic color additives was first announced on July 24, as reported by Bloomberg. "Mars Wrigley North America has been on an innovation journey over the past few years, dedicated to bringing products that provide consumers delicious choices when they treat," the company said in a press release. "In the United States, we are engaged closely with regulators and aware of the increased dialogue and activity regarding colors. All our products meet the high standards and applicable regulations set by food safety authorities around the world, including the FDA." Anton Vincent, president of Mars Wrigley North America, added that the company's approach "is always consumer-focused and science-led." Mars Wrigley said its experts "are exploring alternatives that satisfy scientific safety criteria, technical requirements and consumer preferences." Once the company has identified a "fully effective, scalable solution," it will share updates on timing and specific product commitments, it said. The move makes Mars Wrigley an early entrant to a growing list of major consumer product goods companies offering a choice of naturally colored products. The change comes amid a push from Health and Human Services Secretary Robert F. Kennedy Jr. to crack down on synthetic food additives as part of his initiative to "Make America Healthy Again." Among those efforts are proposals to phase out artificial food dyes in favor of natural alternatives. In June, Kraft Heinz and General Mills announced plans to remove artificial food dyes from some products within the next two years. Several other large food manufacturers -- including PepsiCo, ConAgra, The Hershey Company, McCormick & Co., J.M. Smucker, Nestlé USA and more -- have announced similar plans in recent months. As of May, the U.S. Food and Drug Administration has approved three additional color additives from natural sources that are in line with the Department of Health and Human Services' goals, which can be used in a wide range of products from gum to breakfast cereal. "For too long, our food system has relied on synthetic, petroleum-based dyes that offer no nutritional value and pose unnecessary health risks. We're removing these dyes and approving safe, natural alternatives -- to protect families and support healthier choices," Kennedy said in a statement at the time. Multiple states have also passed legislation to eliminate food dyes from school lunch programs. Solve the daily Crossword
The Hill
17 hours ago
- The Hill
Insurance company reverses claim denial for boy's life-saving brain surgery
HAMBURG, N.Y. (WIVB) — Born in September 2024, Cameron Casaacci is the child that Alyssa and Brad Casacci always wanted. But within hours of Cam's birth, their world was turned upside down. 'They did an MRI on this 1-day-old baby and kind of confirmed the worst: He had a very large stroke on the left side of his brain. [Additional] seizure activity was secondary to that injury,' Alyssa told Nexstar's WIVB. The family was then transferred to Oishei Children's Hospital in Buffalo, New York, where they spent the next 19 days holding out hope for a miracle to save their baby boy. PREVIOUS COVERAGE: New York parents fighting insurance denial for baby's life-saving brain surgery 'It's a really hard pill to swallow when you realize you have the sickest kid in the NICU,' Alyssa said. After boughts of needles and medications, Cam continued to fight. Then a neurosurgeon 'recommended a very drastic surgery.' 'A hemispherectomy, where basically, they go in and they disconnect the left hemisphere of his brain from the right [in order to stop the seizures],' Cam's mother explained. The family sought treatment with a recommended neurosurgeon in Pittsburgh and a date was set for the surgery. As they prepared for the procedure, however, their hopes and prayers came crashing to a halt. The insurance company, Independent Health through New York State Medicaid, denied the surgery because it was out of network and said there were doctors in the area that could perform the surgery. The family, however, was told nobody in Western New York was qualified. 'We talked to insurance. They say, 'Well, this is the game you have to play with the denials,'' Brad said. 'His life and his brain are not a game.' Alyssa and Brad have spent more than a month pushing back on the insurance. 'We appealed with the help of UPMC [University of Pittsburgh Medical Center] and their great staff, letters from our doctors here, our providers,' Alyssa explained. 'They denied that, and then, as of last week, we just went forward trying to exhaust all avenues.' Just days after WIVB's initial report, the decision to deny coverage was reversed. 'A moment of relief that we got what we needed and we can move forward and give this little guy the best childhood and life that he deserves,' Brad Casacci told WIVB on Tuesday. In a statement, Independent Health said this was an important case and that 'they've been actively communicating with the State Department of Health,' adding, 'Medicaid members receive services from in-network providers; however, given the rare nature of the procedure requested, the department has granted us flexibility to approve the procedure at the facility requested without further appeal or delay.' The surgery is now scheduled for next Wednesday, August 20, at UPMC Children's Hospital with Dr. Taylor Able, a pediatric neurosurgeon who specializes in epilepsy surgery. 'We trust him, and he wanted to build that relationship with us,' Brad said. 'But he showed that urgency, he knew Cam needed the surgery, just like we did, sooner rather than later.' 'We just can't wait to move forward and just, you know, let his little brain do beautiful things,' Alyssa said. As the Casaccis prepare for what doctors say will be a six-hour surgery, the family is asking for continued support and prayers as they move on to this next chapter.
Business Wire
2 days ago
- Business Wire
Sapient Publishes Breakthrough rLC-MS Metabolomics Study in Over 26,000 Samples, Revealing Metabolic Aging Clock and Disease Insights
SAN DIEGO--(BUSINESS WIRE)-- Sapient, a leader in multi-omics data generation for biomarker discovery and clinical insight delivery, has published a pioneering study detailing the application of its rLC-MS system for non-targeted metabolomics analysis in more than 26,000 plasma samples, which led to the discovery of key metabolic phenotypes ('metabotypes') that correlate with common diseases and enabled development of a machine learning (ML)-based metabolic aging clock found to accurately predict accelerated aging in various chronic diseases, with dynamic reversal of aging following definitive therapy. The samples were analyzed by rLC-MS to capture over 15,000 metabolites and lipids per sample, providing the first deep view into the comprehensive landscape of human small molecule chemistry. For this study, a subset of samples from Sapient's DynamiQ™ biorepository — comprised of more than 62,000 total plasma samples — were selected from 6,935 individuals to represent diverse demographic backgrounds and disease profiles. The samples were analyzed by rLC-MS to capture over 15,000 metabolites and lipids per sample, providing the first deep view into the comprehensive landscape of human small molecule chemistry. These molecules are derived from both endogenous and exogenous sources and therefore reflect dynamic physiological processes and environmental influences, making them important biomarkers to understand and predict clinically relevant physiological states. Across individuals, biological variation was markedly higher than technical variation, indicating good power to discern biological effects. Using the large-scale dataset generated via rLC-MS, Sapient was able to identify several distinct subpopulations with metabotypes that correlate with heterogeneous disease phenotypes, including strong associations with cardiometabolic disorders. These findings suggest that plasma metabolomics can be used to metabolically define subgroups, predict disease states, and develop molecular diagnostic tools. The rLC-MS dataset was also used to train an ML model to predict biological age and capture individual differences in rate of aging, in particular exploring how chronic human diseases may shorten lifespan. This metabolic aging clock successfully predicted accelerated aging in chronic human disorders as well as reversal of aging in kidney disease patients following transplantation, demonstrating that metabolomics may better capture dynamic changes in aging than biomedical data or epigenetic markers alone. 'These findings demonstrate the discovery power of the rLC-MS platform to capture a broad and dynamic landscape of chemical variation in human plasma, across a large population,' said Jeramie Watrous, PhD, first author on the paper and Co-Founder and Head of Analytical R&D at Sapient. 'The robust, large-scale datasets that can be generated with rLC-MS will substantially increase the ability to identify robust small molecule biomarkers, elucidate novel disease mechanisms, and predict biomedically relevant physiological states.' 'To answer our ambitious questions about shared and unique features of human biology at scale, we had to reimagine the entire technology stack, from our rLC-MS to an AI-driven pipeline for automated feature detection, annotation, and quality control,' said Saumya Tiwari, PhD, co-first author and Co-Founder and Head of Computational R&D Operations at Sapient. 'We built AI-powered custom software and a library of over 13,000 chemical standards to transform raw signal into meaningful biology. The result is a dynamic, high-resolution portrait of human individuality shaped by both biology and environment.' 'We've shown that non-targeted metabolomics data can be very valuable to train predictive models of complex physiological states,' said Tao Long, PhD, MBA, Co-Founder and Head of Data Science at Sapient. 'With our ML-based analyses, we find circulating metabolites hold close association with key human health and disease phenotypes, and can predict and read out complex, dynamic biological processes including biological aging, disease onset, and therapeutic response.' The full paper, entitled 'Rapid Liquid Chromatography-Mass Spectrometry (rLC-MS) for Deep Metabolomics Analysis of Population Scale Studies', can be accessed here. About Sapient Sapient is a leader in multi-omics data generation and insight delivery, providing bespoke services for proteomics, metabolomics, and lipidomics that enable biopharma sponsors to go beyond the genome to accelerate precision drug development. Utilizing cutting-edge, high-throughput mass spectrometry and biocomputational frameworks, Sapient enables comprehensive biomarker-phenotype mapping across thousands of biosamples for discovery of robust protein, metabolite, and lipid biomarkers, drug targets, and clinical signatures of drug response. The company's DynamiQ™ Insights Engine — a longitudinal database of integrated multi-omics and real-world data collected from tens of thousands of samples — enables rapid drug target identification, biomarker discovery and validation, and translational and clinical insights across all stages of drug development. For more information, visit
